Loading
Interpace Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Burnell Thomas W., was filed 25 May 2021.
Interpace Biosciences, Inc.: what insiders have been doing
Interpace Biosciences, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Between 22 October 2025 and 22 October 2026, 4 insiders published 5 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Over the last twelve months, not one insider purchase of Interpace Biosciences, Inc. stock was filed.
With 5 filings in twelve months, the company is quieter than the median of 8 filings across the 277 companies we follow on the same exchange. Looking back to 2016, when coverage begins, insiders filed 9 purchases and no sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 38.7 m USD and net income of 24.6 m USD.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
48
Thresholds
n/a
Buy Volume
€291,591
9 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 227 of 26,286 companies
88.1
score / 100
Value85
Quality91
FCF yld14%
Earn yld64%
EV/EBITDA8.3x
ROE226%
Gross mgn62%
Net mgn63%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$5.30
Analyst consensus
Income statement
RevenueUS$38.7M
Gross profitUS$24.1M62% margin
EBITDAUS$4.8M12% margin
Net incomeUS$24.6M67.6% margin
Valuation
PER (trailing)1.2x
P/Book1.3x
Beta0.63
Balance sheet & cash
Market capUS$31.3M
Total debtUS$1.2M
Free Cash FlowUS$5.5M
Debt / Equity4%
Profitability & ownership
ROE225.7%
ROA11.1%
% insiders91.2%
% institutions0.0%
Last declaration on 20 August 2026
Declarations48 total
1,966,763 shares0Common StockSEC:0001493152-26-039528:0
581,718 shares@ US$1.612.53% mcap91.2% of flowCommon StockSEC:0001493152-26-039528:1
277,009 shares0Common StockSEC:0001493152-26-039495:0
9,405,941 shares@ US$2.02100.0% of flowCommon StockSEC:0001493152-26-007093:0
13,861,386 shares@ US$2.02100.0% of flowCommon StockSEC:0001493152-26-005161:0
15,112 shares0Common StockSEC:0001641172-25-006211:4
1,111 shares0Common StockSEC:0001641172-25-006211:5
1,095 shares0Common StockSEC:0001641172-25-006211:1
7,556 shares0Common StockSEC:0001641172-25-006211:2
6,045 shares0Common StockSEC:0001641172-25-006211:3
7,556 shares0Common StockSEC:0001641172-25-006211:0
10,000 shares0Common StockSEC:0001493152-24-005018:0
25,000 shares0Common StockSEC:0001493152-23-026319:0
10,855 shares@ US$8.688.8% of flowCommon StockSEC:0001493152-21-012889:0
Canonical exit: 19 Aug 2021 (T+90)
50,000 sharesCommon StockSEC:0001493152-21-005913:0
14,946 shares@ US$3.1718.2% of flowCommon StockSEC:0001420506-21-000363:0
Canonical exit: 27 May 2021 (T+90)
16,360 shares@ US$3.0819.4% of flowCommon StockSEC:0001420506-21-000363:1
Canonical exit: 30 May 2021 (T+90)
14,874 shares@ US$3.1718.1% of flowCommon StockSEC:0001420506-21-000363:2
Canonical exit: 27 May 2021 (T+90)
14,726 shares@ US$3.0817.5% of flowCommon StockSEC:0001420506-21-000363:3
Canonical exit: 30 May 2021 (T+90)
8,333 shares@ US$3.1710.1% of flowCommon StockSEC:0001420506-21-000363:4
Canonical exit: 27 May 2021 (T+90)
8,252 shares@ US$3.089.8% of flowCommon StockSEC:0001420506-21-000363:5
Canonical exit: 30 May 2021 (T+90)
2,897 shares@ US$3.173.5% of flowCommon StockSEC:0001420506-21-000363:6
Canonical exit: 27 May 2021 (T+90)
2,862 shares@ US$3.083.4% of flowCommon StockSEC:0001420506-21-000363:7
Canonical exit: 30 May 2021 (T+90)
12,438 shares@ US$4.0247.6% of flowCommon StockSEC:0001493152-21-002395:0
100,000 shares0Common StockSEC:0001493152-20-022839:0
25 of 48 declarations
About Interpace Biosciences, Inc.
Interpace Biosciences, Inc. is a company focused on developing diagnostic tests and biotechnology solutions for the healthcare sector. It aims to improve clinical outcomes through genetic and molecular analyses.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
